Cargando…

Safety and effectiveness of lanthanum carbonate for hyperphosphatemia in chronic kidney disease (CKD) patients: a meta-analysis

OBJECTIVE: The aim of this study was to determine the efficacy and safety of lanthanum carbonate (LC) versus calcium salts, non-LC phosphate binders (PBs), sevelamer, or placebo in patients with chronic kidney disease (CKD). MATERIALS AND METHODS: A literature search on PubMed, Embase, and Cochrane...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Lijuan, Liu, An, Xu, Guoshuang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2021
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8491672/ https://www.ncbi.nlm.nih.gov/pubmed/34602015 http://dx.doi.org/10.1080/0886022X.2021.1986068

Ejemplares similares

The management of hyperphosphatemia by lanthanum carbonate in chronic kidney disease patients
por: Shigematsu, Takashi, et al.
Publicado: (2012)

Effect of lanthanum carbonate and calcium acetate in the treatment of hyperphosphatemia in patients of chronic kidney disease
por: Scaria, P. Thomas, et al.
Publicado: (2009)

Efficacy of crushed lanthanum carbonate for hyperphosphatemia in hemodialysis patients undergoing tube feeding
por: Kitajima, Yukie, et al.
Publicado: (2011)

Lanthanum carbonate for the treatment of hyperphosphatemia in CKD 5D: multicenter, double blind, randomized, controlled trial in mainland China
por: Xu, Jing, et al.
Publicado: (2013)

Management of hyperphosphatemia in patients with end-stage renal disease: focus on lanthanum carbonate
por: Persy, Veerle P, et al.
Publicado: (2009)

Ferric citrate for the treatment of hyperphosphatemia and anemia in patients with chronic kidney disease: a meta-analysis of randomized clinical trials
por: Li, Li, et al.
Publicado: (2022)

NPT-IIb Inhibition Does Not Improve Hyperphosphatemia in CKD
por: Larsson, Tobias E., et al.
Publicado: (2017)

Clinical Evaluation of the Safety, Efficacy and Tolerability of Lanthanum Carbonate in the Management of Hyperphosphatemia in Patients with End-Stage Renal Disease
por: Cernaro, Valeria, et al.
Publicado: (2020)

NaPi-IIb Inhibition for Hyperphosphatemia in CKD Hemodialysis Patients
por: Maruyama, Sonomi, et al.
Publicado: (2020)

Control of hyperphosphatemia and maintenance of calcemia in CKD
por: Carvalho, Aluizio Barbosa, et al.
Publicado: (2021)

Lanthanum carbonate for the control of hyperphosphatemia in chronic renal failure patients: a new oral powder formulation – safety, efficacy, and patient adherence
por: Lloret, MªJesús, et al.
Publicado: (2013)

The Pharmacological Effect and Mechanism of Lanthanum Hydroxide on Vascular Calcification Caused by Chronic Renal Failure Hyperphosphatemia
por: Zhao, Lulu, et al.
Publicado: (2021)

Changes With Lanthanum Carbonate, Calcium Acetate, and Phosphorus Restriction in CKD: A Randomized Controlled Trial
por: Kovesdy, Csaba P., et al.
Publicado: (2018)

Sevelamer carbonate in the treatment of hyperphosphatemia in patients with chronic kidney disease on hemodialysis
por: Savica, Vincenzo, et al.
Publicado: (2008)

Nutritional Guideline for the Management of Mexican Patients with CKD and Hyperphosphatemia
por: Palafox-Serdán, Frida, et al.
Publicado: (2020)

Hyperphosphatemia: The hidden killer in chronic kidney disease
por: Askar, Akram M.
Publicado: (2015)

Hyperphosphatemia Management in Patients with Chronic Kidney Disease
por: Shaman, Ahmed M., et al.
Publicado: (2016)

Effect of low-dose lanthanum carbonate on calcium and phosphorus metabolism in Asian Patients with end-stage renal disease, maintenance hemodialysis and hyperphosphatemia
por: Cui, Xiaofei, et al.
Publicado: (2022)

Elevated Cardiac Markers in Chronic Kidney Disease as a Consequence of Hyperphosphatemia-Induced Cardiac Myocyte Injury
por: Wang, Shu, et al.
Publicado: (2014)

Chronic Kidney Disease, Queensland (CKD.QLD) Registry: Management of CKD With Telenephrology
por: Venuthurupalli, Sree K., et al.
Publicado: (2018)

Prognosis and risk factors of chronic kidney disease progression in patients with diabetic kidney disease and non-diabetic kidney disease: a prospective cohort CKD-ROUTE study
por: Chen, Shengnan, et al.
Publicado: (2022)

Prognostic Significance of Chronic Kidney Disease (CKD-EPI Equation) and Anemia in Patients with Chronic Heart Failure Secondary to Chagas Cardiomyopathy
por: Nakazone, Marcelo Arruda, et al.
Publicado: (2020)

Encephalopathy caused by lanthanum carbonate
por: Fraile, Pilar, et al.
Publicado: (2011)

Intensified treatment of hyperphosphatemia associated with reduction in parathyroid hormone in patients on maintenance hemodialysis
por: Chen, Lan, et al.
Publicado: (2018)

Pharmacology of the Phosphate Binder, Lanthanum Carbonate
por: Damment, Stephen JP
Publicado: (2011)

Efficacy and Safety of Sevelamer Carbonate in Chinese Nondialysis Chronic Kidney Disease Patients with Hyperphosphatemia: A Randomized, Double-Blind, Parallel-Group Study
por: Chen, Wei, et al.
Publicado: (2022)

Hyperphosphatemia Drives Procoagulant Microvesicle Generation in the Rat Partial Nephrectomy Model of CKD
por: Abbasian, Nima, et al.
Publicado: (2020)

Rationale and design of a multicenter Chronic Kidney Disease (CKD) and at-risk for CKD electronic health records-based registry: CURE-CKD
por: Norris, Keith C., et al.
Publicado: (2019)

Targeting Gastrointestinal Transport Proteins to Control Hyperphosphatemia in Chronic Kidney Disease
por: Fouque, Denis, et al.
Publicado: (2018)

Serum sclerostin in vascular calcification in CKD: a meta-analysis
por: Lin, Yan, et al.
Publicado: (2023)

Efficacy and safety of lanthanum carbonate on chronic kidney disease–mineral and bone disorder in dialysis patients: a systematic review
por: Zhang, Chenglong, et al.
Publicado: (2013)

Validation of the EKFC equation for glomerular filtration rate estimation and comparison with the Asian-modified CKD-EPI equation in Chinese chronic kidney disease patients in an external study
por: Zhao, Li, et al.
Publicado: (2023)

Proton pump inhibitors may hinder hypophosphatemic effect of lanthanum carbonate, but not of ferric citrate hydrate or sucroferric oxyhydroxide, in hemodialysis patients
por: Minakuchi, Hitoshi, et al.
Publicado: (2020)

Meta-analysis of the efficacy and safety of sevelamer as hyperphosphatemia therapy for hemodialysis patients
por: Zeng, Qian, et al.
Publicado: (2023)

Phosphate intake, hyperphosphatemia, and kidney function
por: Rubio-Aliaga, Isabel, et al.
Publicado: (2022)

Understudied Hyperphosphatemia (Chronic Kidney Disease) Treatment Targets and New Biological Approaches
por: Anand, Ajeeta, et al.
Publicado: (2023)

The efficacy and safety of roxadustat for anemia in patients with dialysis-dependent chronic kidney disease: a systematic review and meta-analysis
por: Zhou, Qiaoqiao, et al.
Publicado: (2023)

Cost effectiveness of lanthanum carbonate in chronic kidney disease patients in Spain before and during dialysis
por: Gros, Blanca, et al.
Publicado: (2015)

Calcium Acetate or Calcium Carbonate for Hyperphosphatemia of Hemodialysis Patients: A Meta-Analysis
por: Wang, Yong, et al.
Publicado: (2015)

Efficacy of Lanthanum Carbonate and Sevelamer Carbonate as Phosphate Binders in Chronic Kidney Disease—A Comparative Clinical Study
por: Nain, Parminder, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_cjot9ppas6ah8v5nkgv9d2pbq7